Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells

Hirofumi Watanabe1,2, Yusuke Inoue3, Kazuo Tsuchiya1,2

  • 1Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

NPJ Precision Oncology
|March 14, 2025
PubMed

Insights

Small cell lung cancer (SCLC) subtypes normally show mutual exclusivity. Co-expressing key transcription factors (TFs) like ASCL1 and NEUROD1 in SCLC cells causes lethal intolerance, revealing a potential therapeutic vulnerability.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Small cell lung cancer (SCLC) is classified into subtypes based on transcription factor (TF) expression.
  • Intra-tumoral heterogeneity is observed, with subtypes often considered mutually exclusive.

Purpose of the Study:

  • Investigate the mechanism behind SCLC subtype mutual exclusivity.
  • Identify a novel therapeutic vulnerability in SCLC.

Main Methods:

  • Profiled ASCL1, NEUROD1, POU2F3, and YAP1 expression in 151 human SCLC samples.
  • Created inducible co-expression models of TFs in SCLC cell lines.
  • Performed gene expression and ATAC-seq analyses.

Main Results:

  • Observed high mutual exclusivity between ASCL1 and NEUROD1 at the cellular level.
  • Found that co-expression of ASCL1 and NEUROD1 leads to mutual repression, growth inhibition, and apoptosis.
  • Demonstrated lineage reprogramming and chromatin accessibility rewiring upon TF co-expression.
  • Showed NEUROD1 co-expression downregulates BCL2, inducing apoptosis in ASCL1-driven SCLC.

Conclusions:

  • Lethal co-expression intolerance drives mutual exclusivity between ASCL1 and NEUROD1 in SCLC cells.
  • This intolerance represents a potential therapeutic vulnerability for SCLC treatment.